2022 International Congress Archives - Page 2 of 153

Lack of immunogenicity of incobotulinumtoxinA in pediatrics: A pooled analysis

F. Heinen, M. Banach, E. Dabrowski, D. Gaebler-Spira, H. Chambers, S. Schroeder, T. Geister, M. Althaus, A. Hanschmann, S. Berweck (Munich, Germany)
Lack of Toll-like receptor 4 is associated with accumulation of alpha-synuclein in the midbrain Parkinson’s disease mice.

C. Conte, G. Mariucci, R. Cafaro (Perugia, Italy)
Language Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder and de-novo Parkinson’s disease

M. šubert, M. šimek, M. Novotný, T. Tykalová, O. Bezdíček, E. Růžička, K. šonka, P. Dušek, J. Rusz (Prague 6, Czech Republic)
Late Onset Ataxia, Myoclonus, and Cognitive Decline in a Patient with Xeroderma Pigmentosum: A Case Report

J. Modica, A. Hewitt, P. Morrison (Rochester, USA)
Late Onset Hemichorea Of Vascular Origin In A Middle Aged Female With Recent Onset Diabetes

N. Premarathna, A. Fernando, S. Bandusena (Colombo, Sri Lanka)
Late-onset cerebellar ataxia: case report of a new CNV on TTBK2 gene as possible cause of SCA-11

I. Rodríguez (Monterrey, Mexico)
Late-onset Treatment Resistant Isolated Oromandibular Dystonia: A case report

S. Jain, P. Renjen, D. Chaudhary, S. Pandey, A. Goswami (New Delhi, India)
Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)
Leading Therapeutic Molecules Target Transcription Factors Binding to Repressor Region in FXN Gene

V. Swarup, H. Singh, D. Gupta, I. Singh, A. Srivastava (New Delhi, India)
Learning to PERSEVERE: Efficacy and Feasibility of Peer Mentor Support and Caregiver Education in Lewy Body Dementia

J. Fleisher, F. Akram, S. Hess, M. Levin, D. Dodson, G. Stebbins, M. Tosin, B. Ouyang, J. Chodosh (Chicago, USA)
Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease: the PD COMM randomised controlled trial.

C. Sackley, C. Rick, S. Patel, R. Woolley, M. Brady, A. Nicoll, S. Dickson, G. Beaton, C. Smith, H. Nankervis, C. Burton, P. Masterson-Algar, N. Ives, S. Jowett, Z. Abdali, L. Sharp, T. Jeffreys, C. Clarke (London, United Kingdom)
Lentiform fork sign and Wilson Disease

JL. Freitas, MS. Rocha, PC. Matos, I. Torres, L. Corazza, JF. Tasch (São Paulo, Brazil)
Lesion-induced chorea-ballismus in Southwest Finland

E. Mäkinen, J. Joutsa (Turku, Finland)
Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease

B. Muminov, R. Matmurodov, E. Abduqodirov (Tashkent, Uzbekistan)
Levodopa Carbidopa Intestinal Gel in Patients with Deep Brain Stimulation in Parkinson’s disease- First case series from Middle-East Region

S. Mittal, A. Aldakheel, W. Mohammed, T. Alkhairallah, B. Klassen, M. Thomas, T. Maiti, S. Wasti (Abu Dhabi, United Arab Emirates)
Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations

J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)
Levodopa-carbidopa intestinal gel (LCIG) as an add-on therapy to deep brain stimulation (DBS) for managing progressive symptoms of advanced idiopathic Parkinson’s disease during the COVID-19 pandemic: Case Report

M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)
Levodopa-carbidopa intestinal gel infusion and long-term tolerability in Parkinson’s: multicentre, international 13-year follow-up data

V. Leta, L. Batzu, L. Williams, S. Waller, F. Garri, K. Rukavina, M. Parry, S. Jones, J. Griffith, N. Jeyakumar, M. Scharfenort, P. Odin, V. Metta, G. Chung-Faye, P. Dubois, T. Marshall, A. Zecchinelli, F. Del Sorbo, V. Viljaharju, E. Pekkonen, A. Antonini, V. Fung, K. Ray Chaudhuri (London, United Kingdom)
Levodopa-induced unilateral orofacial dystonia in multiple system atrophy : case report and video presentation

C. Dong, H. Sun, S. Liu, P. Chan (Beijing, China)
Levodopa–entacapone–carbidopa intestinal gel infusion for advanced Parkinson’s disease patients – data from a Romanian center

A. Dulamea, T. Barbulescu, C. Banica (Bucharest, Romania)
Levosulpiride and Movement Disorders–A Growing Concern

D. Radhakrishnan, S. Gomathy, R. Rajan, A. Srivastava, A. Das, A. Agarwal, A. Pandit, V. Goyal (New Delhi, India)
Lewy body disease clinical subgroups present similar disease progression rates

C. Abdelnour, C. Young, E. Müller-Oehring, D. Ferreira, M. Shahid, M. Plastini, J. Winer, K. Poston (Stanford, USA)
LFP beta frequency OFF-ON shift in subthalamic nucleus in Parkinson’s disease

K. Sayfulina, V. Filyushkina, A. Gamaleya, E. Belova, A. Tomskiy, A. Sedov (Moscow, Russian Federation)
LIG1 polymorphism modifies the age at onset in patients with Spinocerebellar Ataxia type 2

LE. Almaguer-Mederos, D. Cuello-Almarales, R. Aguilera-Rodríguez, D. Almaguer-Gotay, Y. González-Zaldívar, R. Lamas-González, S. Gispert, G. Auburger (Holguin, Cuba)
Limb myorhythmia treated with chemodenervation: A case report

N. Saez Calveras, M. Bryarly, M. Salinas (Dallas, USA)
Lingual dystonia etiology spectrum in a tertiary center

J. Lopes, M. Magalhães (Porto, Portugal)
Liraglutide once daily versus placebo in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial

T. Wu, C. Bresee, J. Wertheimer, E. Hogg, C. Malatt, E. Tan, H. Pomeroy, G. Obialisi, M. Tagliati (Los Angeles, USA)
Local Field Potential from Subthalamic Nucleus Correlate with Attentional Performance in Parkinson’s Disease

MS. Rocha, A. Fim Neto, B. Bianqueti, J. de Luccas, D. Soriano, L. da Silva, F. Godinho (SAO PAULO, Brazil)
Local Field Potential Recordings in Parkinson’s Disease at Home: A Case Series Report

K. Martinez, V. Madrigal, N. Morelli, A. Singer (Aliso Viejo, USA)
Long non-coding RNAs in Parkinson’s disease: bringing back life to the grey matter?

S. Acharya, A. Lumley, L. Zhang, V. Stopa, Y. Devaux (Strassen, Luxembourg)
Long-read nanopore sequencing for cost-effective and comprehensive analysis of GBA mutations in Norwegian patients with Parkinson’s disease

C. Gabbert, S. Schaake, T. Lüth, C. Klein, J. Aasly, M. Farrer, J. Trinh (Lübeck, Germany)
Long-term Deutetrabenazine Safety on Motor, Psychiatric, and Cognitive Measures in Individuals With Chorea Associated With Huntington Disease

M. Gordon, D. Stamler, J. Savola, N. Gross, H. Barkay, M. Chen, N. Chaijale (West Chester, USA)
Long-term dietary and supplemental intake of folate, vitamin B6 and vitamin B12 and the incidence of Parkinson’s disease in a sample of US women and men

M. Flores Torres, C. Christine, K. Bjornevik, B. Healy, S. Molsberry, A. Hung, D. Blacker, M. Schwarzschild, A. Ascherio (Boston, USA)
Long-term effects of bilateral STN-DBS on speech in Parkinson’s disease patients

F. Cavallieri, A. Gessani, V. Fioravanti, B. Damiano, S. Scaltriti, E. Bardi, M. Corni, F. Antonelli, V. Rispoli, G. Di Rauso, F. Cavalleri, M. Molinari, S. Contardi, E. Menozzi, S. Meletti, G. Biagini, E. Moro, A. Merlo, I. Campanini, C. Budriesi, F. Valzania (Reggio Emilia, Italy)
Long-term efficacy of unilateral high-intensity focused ultrasound subthalamotomy for Parkinson’s Disease

R. Martínez-Fernández, E. Natera-Villalba, J. Máñez-Miró, R. Rodríguez-Rojas, M. Del Alamo, J. Pineda-Pardo, I. Obeso, F. Hernández-Fernández, C. Gasca-Salas, M. Matarazzo, L. Vela, F. Alonso-Frech, J. Obeso (Móstoles, Madrid, Spain)
Long-term follow-up of subthalamic nucleus deep brain stimulation for Parkinson’s disease: survival and disability milestones

R. Barbosa, L. Correia-Guedes, M. Cattoni, P. Pita-Lobo, A. Castro-Caldas, M. Fabbri, P. Bastos, H. Carvalho, L. Albuquerque, S. Reimão, A. Gonçalves Ferreira, J. Ferreirajos, M. Rosa, M. Coelho (Lisbon, Portugal)
Long-Term Neuropsychological Outcomes of Deep Brain Stimulation in Early-Stage Parkinson’s Disease

M. Hacker, M. Tramontana, J. Meystedt, M. Turchan, K. Harper, B. Eoff, R. Fan, F. Ye, T. Davis, P. Konrad, D. Charles (Nashville, USA)
Long-term non-motor and motor outcome after subthalamic stimulation in Parkinson’s disease

A. Castrioto, B. Debu, E. Cousin, P. Pelissier, E. Lhommée, A. Bichon, E. Schmitt, A. Kistner, S. Meoni, E. Seigneuret, S. Chabardes, P. Krack, E. Moro, V. Fraix (La Tronche, France)
Long-term outcome of adaptive DBS using LFP sensing technology

K. Kimura, H. Kishida, N. Ueda, F. Tanaka (Yokohama, Japan)
Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Data from patients who continued past one year in the BeyoND study

S. Isaacson, N. Giladi, F. Stocchi, L. Salin, N. Vostokova, W. Poewe (Boca Raton, USA)
Long-term Safety of Medical Cannabis in Parkinson’s disease: a retrospective case-control study

T. Goldberg, Y. Redlich, T. Fay-Karmon, S. Hassin-Baer, S. Anis (Tel Aviv, Israel)
Long-term wearable tele-rehabilitation of gait for persons with Parkinson’s disease: A feasibility study

G. Lopane, M. Corzani, I. D'Ascanio, V. Petrone, M. Contin, G. Calandra Buonaura, P. Cortelli, F. La Porta, M. Brozgol, N. Giladi, PC. Thumm, JM. Hausdorff, L. Chiari, L. Palmerini (Bologna, Italy)
Longitudinal Analysis of the Corticospinal Tract in Parkinson’s disease Patients

R. Guimaraes, L. Ramalho, B. Campos, F. Cendes (Campinas, Brazil)
Longitudinal Assessessment of Social Cognition in de novo PD patients and its Relationship with Striatal Dopaminergic Innervation

C. Trompeta, C. Gasca-Salas, JA. Pineda Pardo, P. Guida, D. Mata-Marín, M. Hg Monje, A. Sánchez-Ferro, I. Obeso, JA. Obeso (Móstoles, Spain)
Longitudinal assessment of quality of life in early Parkinson’s disease: 5-year follow up study

I. Stankovic, T. Pekmezovic, V. Markovic, N. Dragasevic, I. Petrovic, M. Svetel, V. Kostic (Belgrade, Serbia)
Longitudinal brain perfusion changes correlated with UPDRS Total in a Phase I mesenchymal stem cell trial for Parkinson’s disease

M. Schiess, J. Suescun, C. Adams, E. Tharp, K. Block, M. Doursout, T. Ellmore (Houston, USA)
Longitudinal clinical and biomarkers characteristics of non-manifest LRRK2 G2019S carriers: The PPMI cohort

T. Simuni, K. Merchant, M. Brumm, C. Caspell-Garcia, H. Cho, C. Coffey, L. Chahine, A. Siderowf, C. Tanner, K. Marek, P. Investigators (Chicago, USA)
Longitudinal combined 11C UCB J and 18F FE PE2I PET imaging of presynaptic terminal loss in early Parkinson’s disease.

A. Delva, K. van Laere, W. Vandenberghe (Leuven, Belgium)
Longitudinal evaluation of hypomimia in individuals with Parkinson’s disease using a video analytics tool

P. Yang, M. Islam, A. Abdelkader, W. Rahman, M. Pawlik, S. Jensen-Roberts, E. Waddell, T. Myers, J. Soto, E. Hartman, E. Nnadika, R. Wilson, K. Lizarraga, C. Tarolli, R. Schneider, E. Dorsey, J. Adams, E. Hoque (Rochester, USA)
Longitudinal Exercise is Associated with Reduced Hospitalization Risk in Parkinson’s Disease

G. Kannarkat, M. Rafferty, S. Luo, H. Liu, K. Mills (Baltimore, USA)
Longitudinal predictors of functional dependence in a multicentric Parkinson’s Disease cohort

S. Becker, B. Callahan (Calgary, Canada)
Longitudinal predictors of quality of life in Parkinson’s disease: analysis of NILS cohort data at four years follow up

C. Rodriguez-Blazquez, MJ. Forjaz, A. Rizos, P. Martinez-Martin, KR. Chaudhuri (Madrid, Spain)
Longitudinal Program to Prevent PD (LoPP-PD): Multimodal Risk Stratification Informs Personalized Intervention

K. Niotis, K. Akiyoshi, R. Isaacson, S. Isaacson (New York, USA)
Longitudinal study of clinical and neurophysiological features of essential tremor

L. Angelini, A. de Biase, G. Paparella, A. Di Vita, M. Panfili, A. Maraone, R. Margiotta, A. Berardelli, M. Bologna (Rome, Italy)
Longitudinal study of clinical symptoms associated with psychosis in Parkinson’s disease without dementia

J. Flanigan, M. Harrison, B. Shah, J. Patrie, K. Wyman-Chick, W. Dalrymple, S. Sperling, M. Barrett (Charlottesville, USA)
Longitudinal study of Parkinson’s disease-related pattern with resting state functional MRI

A. Vo, N. Nguyen, D. Eidelberg (Manhasset, USA)
Longitudinal white matter microstructural changes in the prodromal phase of PD: A 2 year prospective study

A. Droby, A. Yoffe-Vasiliev, RM. Hutchison, S. Paz, J. Cedarbaum, N. Giladi, A. Mirelman, A. Thaler (Tel Aviv, Israel)
Low-dose lithium therapy associated with increased PBMC Nurr1 and SOD1 expression in Parkinson’s disease: a pilot study.

T. Guttuso, JR., R. Shepherd, M. Tamano, M. Ramanathan, V. Frerichs, L. Frick (Williamsville, USA)
Lower-limb dystonia as an explanation for freezing of gait responsive to cueing in Parkinson’s Disease

M. Dias, M. Soares (Lisbon, Portugal)
LRRK2 and GBA major variants in the New York Mount Sinai BioMe Biobank

A. Yoo, R. Ortega, V. Katsnelson, A. Debebe, A. Rendon, M. Picker, D. Raymond, S. Bressman, L. Ozelius, I. Peter, R. Saunders-Pullman (New York, USA)
LRRK2 Inhibition by BIIB122: Trial designs for two efficacy and safety studies in Parkinson’s disease patients with and without LRRK2 mutations (Lighthouse and Luma)

J. Shirvan, D. Jennings, P. Wang, R. Maciuca, S. Sahu, F. Sedarati, A. Kay, K. Fraser, S. Huntwork-Rodriguez, M. Yang, M. Levee, P. Chin, T. Dam (Cambridge, USA)
Lymphocyte count/neutrophil-to-lymphocyte ratio and mild cognitive impairment in Parkinson’s disease

E. Contaldi, L. Magistrelli, S. Gallo, C. Comi (Novara, Italy)